Letter to the editor

Twenty years of inhaled insulin: promise, setbacks, and future directions

Meriem Gaddas^1,2, Imen Ben Saida^1,3, Helmi Ben Saad¹[*]^,2

EXCLI J 2025;24:Doc573



Insulin-dependent diabetes mellitus (DM) is a severe chronic condition requiring continuous medical management to prevent life-threatening complications (ADAPPC, 2025[1]). The cornerstone of treatment is insulin therapy, which is essential to maintain glycemic control in patients with this condition (Mishra et al., 2021[19]). In daily practice, insulin is primarily administered via subcutaneous injections, a method that, while effective (WHO, 2021[25]), presents several inconveniences, including lipodystrophy, pain, and allergic reactions, which can affect insulin absorption and efficacy (Maikawa et al., 2021[16]). Consequently, alternative delivery methods, including inhaled insulin, have been explored to improve patient outcomes and adherence to treatment (Cheng et al., 2021[8]). Research on inhaled insulin are few, and on February 5, 2025, a request based on (inhaled insulin [Title]) found 262 papers indexed in PubMed. These papers were published between 1997 and 2024 (ie; annual rate of 2.2 papers), and the peaks of papers were in 2005 and 2006 (n=42 each). This editorial reviewed the 20-year evolution of inhaled insulin, highlighting its benefits, limitations, and challenges. It also explored its future in the context of innovations in DM management.

The first inhaled insulin (Exubera), released in 2006, was approved by the Food and Drug Administration and launched with great fanfare (Bellary and Barnett, 2006[4]). It was presented as an alternative to cumbersome subcutaneous injections, with comparable efficacy and absorption (Perera et al., 2002[21]), and promising great comfort and adherence for patients (Cunningham and Tanner, 2020[9], Rave et al., 2005[24]). The inhaled route of insulin administration has the advantage of a large, well-irrigated exchange surface (ie; the alveolar-capillary surface area, estimated at 75-100 m² (Borghardt et al., 2018[6]), enabling efficient absorption and a reduction in systemic side-effects (Borghardt et al., 2018[6]). The low metabolic activity of the lungs provides protection against the peptide degradation (Borghardt et al., 2018[6]), which is the main obstacle to the development of oral insulin (Wong et al., 2016[26]). In addition, respiratory administration avoids the hepatic degradation of insulin, which can be as high as 80%, during the 'first pass' (Meier et al., 2005[18]). However, a year after it was launched, Exubera had not met with the commercial success expected, leading to its withdrawal and a drop in interest in development projects in this area. This setback was attributed to its high cost, the complexity of its administration, and the appearance of contraindications in certain populations (Rashid et al., 2015[23]).

The experiment was repeated in 2014, with Afrezza (Technospher insulin), which was presented as a major innovation (Goldberg and Wong, 2015[11]). Disappointment with this compound was swift, given the successive complaints about its bioavailability and, above all, its therapeutic safety (Goldberg and Wong, 2015[11]). On the one hand, despite its faster onset (ie; 7-15 minutes), Afrezza had a short duration of action (ie; 2-6 hours) (Grant et al., 2022[12]), and exhibited inter-individual variability, necessitating frequent adjustments and even the combined use of other forms of insulin (Goldberg and Wong, 2015[11]). On the other hand, Afrezza had pulmonary irritation effects, requiring spirometry to be performed before initiating treatment (Mudaliar and Henry, 2007[20]). Almost two years after its launch, serious reservations had been expressed about the potential deleterious effects of Afrezza on lung function, involving a decline in spirometric data, with suspicions of an increased risk of lung cancer, particularly in smokers (McGill et al., 2020[17]). This fear may have been legitimate insofar as it has been established that insulin medication is significantly associated with the risk of cancer (Chen et al., 2023[7], Zhong and Mao, 2022[28]). On this point, it should be emphasized that the association between inhaled insulin and lung cancer has never been demonstrated, and these fears are based on the like-growth factor property of insulin (Rashid et al., 2015[23]). In addition, this hypothetical association stems from observations in a clinical trial of Exubera, where two patients with a history of heavy smoking developed cancer (McGill et al., 2020[17]). Several studies dating from after 2020 had demonstrated the absence of any significant long-term carcinological risk associated with the use of inhaled insulin (Afrezza in particular) (Greene et al., 2021[13]). These results were demonstrated in animals (Greene et al., 2021[13]), and approved in humans by a clinical trial involving 5500 patients, in which Afrezza's adverse pulmonary effects were comparable to those attributed to other treatments, with the exception of irritant cough (McGill et al., 2020[17]). Similarly, the decline in respiratory function would be of a reversible functional nature, with no objective organic support by radiology (McGill et al., 2020[17]). However, although the most-updated data would suggest an acceptable level of safety, it remains preferable to retain a warning notice for patients with pre-existing chronic respiratory conditions (Afreza, 2023[2]) (Box 1).

Compared with injectable insulin, inhaled insulin has a lower overall bioavailability due to losses in the airways, making it necessary to increase doses (Bellary and Barnett, 2006[4]). The bioavailability of inhaled insulin may be influenced by chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) (Mudaliar and Henry, 2007[20]). In fact, absorption is thought to be 30-40% lower in asthmatics (Mudaliar and Henry, 2007[20]), which means that a bronchodilator needs to be administered before inhaled insulin to optimize absorption, and doses need to be increased (Petersen et al., 2010[22]). In COPD patients, the absorption of inhaled insulin is described as variable (Mudaliar and Henry, 2007[20]). Smoking has a significant influence on the absorption of inhaled insulin, since smokers have faster and greater absorption (Becker et al., 2006[3]). This latter effect is reversible after smoking cessation (Becker et al., 2006[3]). This explains why inhaled insulin was not recommended for diabetic patients who continue to smoke (Becker et al., 2006[3]). A 2022 systematic review and meta-analysis of 13 low-bias randomized clinical trials comparing inhaled insulin with conventional insulin found that inhaled insulin is as effective as subcutaneous insulin in patients with type 1 DM (Khan et al., 2022[15]). Inhaled insulin was also associated with less weight gain and fewer hypoglycemic episodes, with similar effects on blood glucose levels and no increased risk of adverse events (Khan et al., 2022[15]). These findings suggest that inhaled insulin may be a suitable alternative for patients concerned about injection compliance or weight gain.

Recent trials suggest that inhaled insulin holds promise as an alternative for DM management (Hirsch et al., 2024[14]). Inhaled insulin currently appears to be most effective for achieving optimal post-meal blood sugar control when used in conjunction with basal insulin injections (Hirsch et al., 2024[14]). The Phase 4 INHALE-3 trial (MannKind) demonstrated that Afrezza plus basal insulin injections resulted in better post-meal glucose excursions compared to usual care (Hirsch et al., 2024[14]). Furthermore, preliminary data from the Phase 3, open-label, randomized INHALE-1 study evaluating Afrezza in combination with basal insulin in pediatric DM are also promising (Hirsch et al., 2024[14]). Ongoing long-term safety trials conducted by MannKind will further assess the safety and tolerability of Afrezza in adults with type 1 or type 2 DM, providing additional data on its long-term effects, particularly on the lungs (Hirsch et al., 2024[14]).

There are numerous advances on the market in the formulation of recombinant insulins, which aim to optimize the management of DM while also optimizing patients' quality of life (Bolli et al., 2022[5], Maikawa et al., 2021[16]). These formulations are potential “competitors” to inhaled insulin, such as rapid- and long-acting human insulin analogues, which closely mimic the physiological secretory profile of insulin (Bolli et al., 2022[5]), weekly insulin (AFRE) (Bolli et al., 2022[5]), and injection pens, which are more convenient and increasingly painless (Bolli et al., 2022[5]). The challenge of new inhaled insulin formulations is to allow a macromolecule such as insulin to pass through a pulmonary epithelial barrier specifically designed to stop the intrusion of exogenous agents (Rashid et al., 2015[23]). Among these innovative formulations are those based on advances in nanotechnology through the use of nanoparticles (Zhang et al., 2021[27]). The latter are agents for encapsulating insulin, aimed at improving its safety during transepithelial transport and absorption, which would guarantee greater stability (Zhang et al., 2021[27]). Some of these formulations would also allow control of the release time of the encapsulated insulin (rapid or long-lasting effect) (Zhang et al., 2021[27]). Although promising, inhaled nanopeptide insulins are still not approved for clinical use (Zhang et al., 2021[27]). There are certain limitations to their commercialization in terms of cost and long-term safety (eg; challenges relating to the stability of formulations and the disposal of materials used), since these are molecules in the experimental phase, under evaluation (Zhang et al., 2021[27]).

In conclusion, despite all the efforts made over the last twenty years (ie; 2004-2024) to develop inhaled insulins, these efforts have not been crowned with success, as the bioavailability of these preparations remains low and unpredictable compared with injectable insulin. This lack of success is likely further compounded by poor publicity and marketing since market release, particularly the historical failure of Exubera, which has contributed to hesitancy among patients and prescribers.

Declaration

The authors wish to disclose that an artificial intelligence tool (i.e., ChatGPT 3.5 ephemeral) was utilized to enhance the manuscript's wording, readability, and language quality. The tool was used only for language refinement and not for generating text (Dergaa and Ben Saad, 2023[10]).

References